NCT02443883已完成2 期
Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 164
- 试验地点
- 9
- 主要终点
- Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
研究概览
简要总结
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant has a histopathologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction (GEJ).
- •The participant has documented disease progression during or within 4 months after the last dose of first-line chemotherapy for metastatic disease, or during or within 6 months after the last dose of neoadjuvant or adjuvant therapy.
- •The participant received combination chemotherapy prior to disease progression.
- •Prior chemotherapy regimens must include a platinum and/or a fluoropyrimidine component and must not include a taxane or antiangiogenic agent.
- •The participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
- •Patients are eligible if they are considered not appropriate, for whatever reason, for treatment with ramucirumab in combination with paclitaxel.
- •The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •The participant has adequate organ function, including:
- •Total bilirubin 1.5 × the upper limit of institutional normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN are acceptable.
- •Serum creatinine 1.5 × ULN or calculated creatinine clearance (per the Cockcroft-Gault formula or equivalent and/or 24-hour urine collection) 60 milliliters/minute (mL/min).
- •Urinary protein is <2+ on dipstick or routine urinalysis.
- •Absolute neutrophil count 1.5 × 10^9/Liter (L), platelets 100 × 10^9/L, and hemoglobin 9 g/deciliter (dL) (5.58 millimoles/Liter).
- •International normalized ratio 1.5 × ULN or prothrombin time 5 seconds above ULN.
- •Partial thromboplastin time 5 seconds above ULN.
- •The participant has an estimated life expectancy of 12 weeks in the judgment of the investigator.
- •The participant, if female and of child-bearing potential, must have a negative serum or urine pregnancy test within 7 days prior to randomization.
排除标准
- •The participant has squamous cell or undifferentiated gastric cancer.
- •The participant is receiving chronic therapy with any of the following within 7 days prior to randomization:
- •Nonsteroidal anti-inflammatory agents (NSAIDs; such as indomethacin, ibuprofen, naproxen, or similar agents), or
- •Other anti-platelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide). Aspirin use at doses up to 325 milligrams (mg)/day is permitted.
- •The participant received radiotherapy within 14 days prior to randomization.
- •The participant received >1 line of prior therapy for the treatment of locally advanced and unresectable or metastatic gastric or GEJ (Siewert Types I-III) adenocarcinoma.
- •The participant received previous treatment with agents targeting the vascular endothelial growth factor (VEGF)/VEGF receptor 2 signaling pathway.
- •The participant has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.
- •The participant experienced any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization.
- •The participant has symptomatic congestive heart failure (New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia.
- •The participant has uncontrolled hypertension, as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, prior to initiating study treatment, despite antihypertensive intervention.
- •The participant underwent major surgery within 28 days prior to randomization or central venous access device placement within 7 days prior to randomization.
- •The participant has a history of gastrointestinal perforation or fistula within 6 months prior to randomization.
- •The participant has any condition (for example, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggests that the participant is, in the investigator's opinion, not an appropriate candidate for the study.
研究组 & 干预措施
Ramucirumab Regimen 1
Experimental
Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
干预措施: Ramucirumab (Drug)
Ramucirumab Regimen 2
Experimental
Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
干预措施: Ramucirumab (Drug)
Ramucirumab Regimen 3
Experimental
Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
干预措施: Ramucirumab (Drug)
Ramucirumab Regimen 4
Experimental
Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
干预措施: Ramucirumab (Drug)
结局指标
主要结局
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
时间窗: Day 29, 43, 71 and 85: predose
The Cmin is the minimum observed serum concentration of ramucirumab.
次要结局
- Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies(Predose Cycle 1 Through Short Term Follow Up (Up to 5 Months))
- Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment(Baseline until the first 6-week tumor assessment)
研究者
研究点 (9)
Loading locations...
相似试验
终止
2 期
Study of KB003 In Biologics-Inadequate Rheumatoid ArthritisRheumatoid ArthritisNCT00995449Humanigen, Inc.9
已完成
2 期
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCystic FibrosisNCT03911713Vertex Pharmaceuticals Incorporated77
已完成
1 期
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).Healthy VolunteershATTR AmyloidosisNCT03728634Ionis Pharmaceuticals, Inc.47
撤回
2 期
Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery PatientsCardiopulmonary BypassHypotensionNCT00482287Meditor Pharmaceuticals Ltd.
已完成
2 期
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)Nonalcoholic SteatohepatitisNCT00740610Gilead Sciences124